Related Experiment Videos
[Cytotoxic chemotherapy in elderly patients: present and future]
1Départment de médecine carcinologique, centre Léon-Bérard, Lyon, France.
Bulletin Du Cancer
|July 1, 1995
Summary
Chemotherapy in elderly cancer patients is toxic. Adjusting drug doses based on biological age and physiological criteria, rather than chronological age, can improve treatment outcomes and reduce toxicity in older adults.
Area of Science:
- Geriatric Oncology
- Pharmacokinetics
- Chemotherapy
Context:
- Elderly cancer patients represent over 50% of treated malignancies in France.
- Chemotherapy is effective but more toxic in the elderly due to physiological heterogeneity.
- Empirical dose reduction is common, leading to conflicting literature on efficacy and toxicity.
Purpose:
- To explore adjusting chemotherapy regimens based on physiological criteria, specifically biological age, for elderly cancer patients.
- To highlight the limitations of chronological age in describing elderly patients' heterogeneity.
- To investigate the potential of population pharmacokinetic models for optimizing cytostatic drug dosing in older adults.
Summary:
- Biological age, assessed through measurable variables, offers a better representation of physiological status than chronological age in the elderly.
- Age-related physiological variations significantly impact pharmacokinetic data in older individuals.
- Population pharmacokinetic models, Bayesian fitting, and adaptive control show promise for personalized cytostatic dose adjustments in the elderly.
Impact:
- Personalized chemotherapy dosing can mitigate toxicity and potentially improve treatment efficacy in elderly cancer patients.
- This approach addresses the significant heterogeneity within the elderly population.
- Further prospective studies are needed to validate these advanced pharmacokinetic modeling techniques for routine use in geriatric oncology.